Nay Htyte, MD
Cardiovascular Disease · Brooklyn, NYNPI 1639308299
Payments from drug & device makers
Across 129 payments — averaging $62.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$4K
- Medtronic$826
- Tactile Systems Technology Inc$354
- Abbott$323
- Amgen$255
- Novartis$190
- plus $2K from 23 others
What the payments were for
- Travel & lodging$2,03325%
- Food & beverage$3,91549%
- Other$2,06126%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 5 | $4,390 |
| Medtronic | 15 | $826 |
| Tactile Systems Technology Inc | 7 | $354 |
| Abbott | 2 | $323 |
| Amgen | 9 | $255 |
| Novartis | 10 | $190 |
| Boehringer Ingelheim | 10 | $189 |
| AstraZeneca | 9 | $171 |
| Johnson & Johnson | 10 | $162 |
| Bayer | 8 | $148 |
| Inari Medical, Inc. | 1 | $147 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $146 |
| Pfizer | 6 | $110 |
| Alnylam Pharmaceuticals Inc. | 4 | $98 |
| Merck | 4 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $52 |
| Boston Scientific | 2 | $47 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Edwards Lifesciences | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Advanced Oxygen Therapy Inc. | 1 | $33 |
| GSK | 1 | $24 |
| Heartflow, Inc. | 1 | $24 |
| Abiomed | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Coala Life Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure EVLT$2,061
- TurboHawk$329
- Accent Pacemaker$171
- MitraClip$152
- FLOWTRIEVER CATHETER, S$147
- CT THROMBECTOMY SYSTEM KIT$147
- Flexitouch Plus$128
- Entre Plus$128
- Repatha$125
How this compares
$8,009 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $98,279 |
| EntrestoSacubitril/Valsartan | 72 | $96,523 |
| XareltoRivaroxaban | 46 | $57,396 |
| FarxigaDapagliflozin Propanediol | 17 | $25,244 |
| BrilintaTicagrelor | 17 | $18,344 |
| JardianceEmpagliflozin | 14 | $12,382 |
| Ranolazine ErRanolazine | 26 | $6,481 |
| Atorvastatin Calcium | 242 | $3,097 |
| Metoprolol Succinate | 178 | $2,978 |
| Rosuvastatin Calcium | 99 | $2,175 |
| Cilostazol | 54 | $1,307 |
| Amlodipine Besylate | 206 | $1,223 |
| Nifedipine ErNifedipine | 37 | $975 |
| Valsartan | 31 | $939 |
| Carvedilol | 110 | $917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $110 | $98,27978 claims |
| NovartisEntresto | $190 | $96,52372 claims |
| Johnson & JohnsonXarelto | $162 | $57,39646 claims |
| AstraZenecaFarxiga, Brilinta | $171 | $43,58834 claims |
| Boehringer IngelheimJardiance | $189 | $12,38214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$1.1M
- Ozgen DoganBrooklyn$404K
- Warren WexelmanBrooklyn$396K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.